Cargando…

Direct Effects of PPARα Agonists on Retinal Inflammation and Angiogenesis May Explain How Fenofibrate Lowers Risk of Severe Proliferative Diabetic Retinopathy

Detalles Bibliográficos
Autor principal:	Abcouwer, Steven F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526047/ https://www.ncbi.nlm.nih.gov/pubmed/23258912 http://dx.doi.org/10.2337/db12-1223

Ejemplares similares

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone
por: Syversen, Unni, et al.
Publicado: (2009)

Limited Hyperoxia-Induced Proliferative Retinopathy (LHIPR) as a Model of Retinal Fibrosis, Angiogenesis, and Inflammation
por: Corano Scheri, Katia, et al.
Publicado: (2023)

The whole transcriptome effects of the PPARα agonist fenofibrate on livers of hepatocyte humanized mice
por: de la Rosa Rodriguez, Montserrat A., et al.
Publicado: (2018)

Müller Cell–Microglia Cross Talk Drives Neuroinflammation in Diabetic Retinopathy
por: Abcouwer, Steven F.
Publicado: (2017)

The Peroxisome Proliferator-Activated Receptor (PPAR) α Agonist Fenofibrate Suppresses Chemically Induced Lung Alveolar Proliferative Lesions in Male Obese Hyperlipidemic Mice
por: Kuno, Toshiya, et al.
Publicado: (2014)

The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia
por: Rolland, Benjamin, et al.
Publicado: (2012)

HMGB1 Is Involved in the Protective Effect of the PPARα Agonist Fenofibrate against Cardiac Hypertrophy
por: Jia, Zhankui, et al.
Publicado: (2014)

PPAR-α Agonist Fenofibrate Decreased RANTES Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2016)

The PPARα agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism()()
por: Huang, Jianfeng, et al.
Publicado: (2013)

Potent and PPARα-independent anti-proliferative action of the hypolipidemic drug fenofibrate in VEGF-dependent angiosarcomas in vitro
por: Majeed, Yasser, et al.
Publicado: (2019)

In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer
por: Saidi, Samir A, et al.
Publicado: (2006)

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis
por: Bao, Wen, et al.
Publicado: (2021)

PPAR-α Agonist Fenofibrate Decreased Serum Irisin Levels in Type 2 Diabetes Patients with Hypertriglyceridemia
por: Feng, Xiaomeng, et al.
Publicado: (2015)

PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
por: Liu, Tiantian, et al.
Publicado: (2023)

PPARα Agonist Oral Therapy in Diabetic Retinopathy
por: Tomita, Yohei, et al.
Publicado: (2020)

PPARα Agonist Fenofibrate Reduced the Secreting Load of β-Cells in Hypertriglyceridemia Patients with Normal Glucose Tolerance
por: Liu, Jia, et al.
Publicado: (2016)

PPAR-α Agonist Fenofibrate Suppressed the Formation of Ocular Surface Squamous Metaplasia Induced by Topical Benzalkonium Chloride
por: He, Huan, et al.
Publicado: (2020)

Profound Modification of Fatty Acid Profile and Endocannabinoid-Related Mediators in PPARα Agonist Fenofibrate-Treated Mice
por: Murru, Elisabetta, et al.
Publicado: (2022)

Receptor-associated prorenin system contributes to development of inflammation and angiogenesis in proliferative diabetic retinopathy
por: Kanda, Atsuhiro, et al.
Publicado: (2016)

The PPARα agonist fenofibrate attenuates disruption of dopamine function in a maternal immune activation rat model of schizophrenia
por: De Felice, Marta, et al.
Publicado: (2018)

The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
por: Stunes, Astrid K, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

PPAR-α Agonist Fenofibrate Reduces Insulin Resistance in Impaired Glucose Tolerance Patients with Hypertriglyceridemia: A Cross-Sectional Study
por: Feng, Xiaomeng, et al.
Publicado: (2017)

Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension
por: Li, Chuan-Bao, et al.
Publicado: (2009)

Commentary: Management of proliferative vitreoretinopathy in recurrent retinal detachment
por: Babu, Naresh, et al.
Publicado: (2020)

Commentary: Role of hyperhomocysteinemia in proliferative diabetic retinopathy: A case–control study
por: Ramasamy, Kim, et al.
Publicado: (2018)

Commentary: Vitrectomy for proliferative diabetic retinopathy in patients with type 1 diabetes mellitus
por: Tekchandani, Uday, et al.
Publicado: (2021)

L-carnitine and PPARα-agonist fenofibrate are involved in the regulation of Carnitine Acetyltransferase (CrAT) mRNA levels in murine liver cells
por: Kienesberger, Klemens, et al.
Publicado: (2014)

The PPARα Agonist Fenofibrate Prevents Formation of Protein Aggregates (Mallory-Denk bodies) in a Murine Model of Steatohepatitis-like Hepatotoxicity
por: Nikam, Aniket, et al.
Publicado: (2018)

The case for intraocular delivery of PPAR agonists in the treatment of diabetic retinopathy
por: Treacy, Maxwell P, et al.
Publicado: (2012)

CD40 Ligand–CD40 Interaction Is an Intermediary between Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy
por: Abu El-Asrar, Ahmed M., et al.
Publicado: (2023)

Periostin and tenascin-C interaction promotes angiogenesis in ischemic proliferative retinopathy
por: Kubo, Yuki, et al.
Publicado: (2020)

Effects of fenofibrate on inflammatory cytokines in diabetic retinopathy patients
por: Ju, Hai-Bing, et al.
Publicado: (2017)

Myeloid cell modulation by a GLP-1 receptor agonist regulates retinal angiogenesis in ischemic retinopathy
por: Zhou, Lingli, et al.
Publicado: (2021)

CD146/Soluble CD146 Pathway Is a Novel Biomarker of Angiogenesis and Inflammation in Proliferative Diabetic Retinopathy
por: Abu El-Asrar, Ahmed M., et al.
Publicado: (2021)

Therapeutic Effects of PPARα Agonists on Diabetic Retinopathy in Type 1 Diabetes Models
por: Chen, Ying, et al.
Publicado: (2013)

Post-vitrectomy delayed retinal breaks in proliferative diabetic retinopathy
por: Venkatesh, Ramesh, et al.
Publicado: (2023)

PPAR-α Agonist Fenofibrate Prevented Diabetic Nephropathy by Inhibiting M1 Macrophages via Improving Endothelial Cell Function in db/db Mice
por: Feng, Xiaomeng, et al.
Publicado: (2021)

PPAR-α Agonist Fenofibrate Ameliorates Sjögren Syndrome–Like Dacryoadenitis by Modulating Th1/Th17 and Treg Cell Responses in NOD Mice
por: Guo, Xingyi, et al.
Publicado: (2022)

New Lipid Mediators in Retinal Angiogenesis and Retinopathy
por: Fleming, Ingrid
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4mun8gk0nhqjha5jtaur7ijv8d